GenomeQuest and Pathogenica Partner to Offer Genome-based Infectious Disease Discovery Services
GenomeQuest and Pathogenica Partner to Offer
Genome-based Infectious Disease Discovery Services
WESTBOROUGH, Mass. and Cambridge, Mass., July 14, 2011 — GenomeQuest and Pathogenica have announced a strategic partnership to offer discovery services in infectious disease research, including the interaction between the human microbiome and human genome.
This partnership combines Pathogenica’s technology for detecting and subselecting pathogen genomes in human tissue with GenomeQuest’s large-scale whole genome, exome, and microbiome analysis.
The targt applications span basic research through clinical trial endpoint evaluation and focus on infection therapeutics in which both the pathogen genotype and the human genotype influence the treatment outcome. This will enable pharmaceutical companies to rapidly examine combined pathogen/host genetics in thousands of human infectious disease samples.
“By combining our pathogen detection system with the informatics and analysis tools available through GenomeQuest, we believe we provide an important advancement for infectious disease research,” said Yemi Adesokan, Ph.D., co-founder and chief executive officer of Pathogenica.
Applications for this research-use only offering will include:
- Viral drug resistance studies in pre-clinical or clinical development
- Co-sequencing of viral drug resistance mutations and human exome samples to predict drug therapy response
- Custom infectious disease assays combined with deep sequencing and analysis to identify mutant infectious strains in human or mouse samples
- Infectious disease biomarker development
The companies will immediately begin collaboration on target selection, assay customization, and validation studies.
“Pathogenica is enabling new discoveries in infectious disease with a clear path to clinical applications. Our partnership with them harnesses the power of next-generation sequencing to examine pathogen-host relationships in pharmaceutical research,” said Richard Resnick, chief executive officer of GenomeQuest.
For more information on the combined offering, please contact GenomeQuest’s business development office at gq-pg
genomequest
com (gq-pggenomequestcom) .
About GenomeQuest
GenomeQuest is a global provider of large-scale genomic software applications. Based on a whole/multi-genome hosting platform, the company’s products include GQ-IP for global research of genomic sequence intellectual property; GQ-Dx, the industry’s first clinical decision-support system for whole-genome diagnostics; and GQ-Research, a research platform for teams to store, manage, and analyze genomic information at whole/multi-genome scales. GenomeQuest serves major pharmaceutical companies, global agriculture firms, biotech firms, IP legal groups, genome centers, academic research centers, diagnostic companies and labs, and universities around the world.
Learn more at www.genomequest.com.
About Pathogenica
Pathogenica, based in Cambridge, Mass., was founded in 2009 to pioneer commercial applications of pathogen sequencing. Pathogenica applies next-generation DNA sequencing technology for rapid multiplex identification of pathogens, drug resistance genes and toxins in patient samples. The founding scientific advisory board (SAB) is comprised of distinguished scientists in the field, including George Church, Harvard Medical School, Ron Davis, Stanford University, W. Ian Lipkin, Columbia University, Andrew Onderdonk, Harvard Medical School, and Kun Zhang, University of California, San Diego.
Pathogenica’s high throughput pathogen detection system is expected to enable rapid and highly sensitive detection of a wide variety of pathogens from patient samples using just a common assay protocol. www.pathogenica.com
###
Contact: David Olmos
Waggener Edstrom Worldwide
dolmoswaggeneredstromcom
415-547-7039
